What is TAP?

TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.

Since its establishment in 2007, TAP has invested more than $120 million in over 60 projects.

Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA).

Currently, there are more than 20 LLS-supported assets or companies in clinical development including 4 ongoing or planned registration-enabling studies (click here for portfolio).